Skip to main content
Premium Trial:

Request an Annual Quote

CapitalBio TB Tests Cleared in China

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Molecular diagnostics and genetic analysis products developer CapitalBio has received certification from China's State Food and Drug Administration for two microarray-based tests and for one amplification-based test for tuberculosis.

The two microarray assays can identify tuberculosis from spit samples, and they were developed for use with the company's LuxScan scanning and analysis tools, according to firm, which is based in Beijing.

The amplification test is used to quickly distinguish M. tuberculosis from non-tuberculosis mycobacteria (NTM).

The three TB tests recently received CE Mark certifications in the European Union.

"CapitalBio recently received SFDA certificates for two other IVD products, an antinuclear antibody test array kit and deafness gene mutation detection array kit, which also applied pioneering microarray technologies," CapitalBio CEO Jing Cheng said in a statement.

Cheng said that the company expects to receive further SFDA approval for nine additional products before the end of May, including microbead-based assays for detection of diabetes and thyroid diseases.

The Scan

Missed Early Cases

A retrospective analysis of blood samples suggests early SARS-CoV-2 infections may have been missed in the US, the New York Times reports.

Limited Journal Editor Diversity

A survey finds low diversity among scientific and medical journal editors, according to The Scientist.

How Much of a Threat?

Science writes that need for a provision aimed at shoring up genomic data security within a new US bill is being questioned.

PNAS Papers on Historic Helicobacter Spread, Brain Development, C. difficile RNAs

In PNAS this week: Helicobacter genetic diversity gives insight into human migrations, gene expression patterns of brain development, and more.